What is tinea infection of the lower hairline in a patient with vitiligo and how should it be managed?

Tinea Infection of the Lower Hairline in a Patient with Vitiligo

When tinea infection occurs at the lower hairline in a patient with vitiligo, treat it as standard tinea capitis with oral antifungal therapy—the vitiligo does not alter the treatment approach, but be aware that immunosuppressive treatments for vitiligo (like topical ruxolitinib) may increase susceptibility to fungal infections.

Understanding the Clinical Scenario

This presentation involves two distinct dermatologic conditions occurring simultaneously:

• Tinea capitis/hairline infection: A dermatophyte fungal infection affecting the scalp and hair follicles
• Vitiligo: An autoimmune depigmentation disorder that does not directly predispose to fungal infections

The key clinical consideration is whether the patient is receiving immunosuppressive therapy for vitiligo, as this can increase fungal infection risk 1.

Diagnosis of Tinea at the Hairline

Confirm the diagnosis before treating, as clinical diagnosis alone is unreliable 2. The presence of vitiligo can make visual assessment more challenging due to altered pigmentation patterns.

Diagnostic Steps:

• Obtain specimens via scalp scraping, hair pluck, brush, or swab from affected areas 3
• Process for both microscopy and culture to identify the causative organism 3
• Look for cardinal signs: scaling, lymphadenopathy, and alopecia 3
• Consider that hypopigmented areas from vitiligo may mask or confuse the clinical picture 4

Start treatment empirically if cardinal signs are present (scale, lymphadenopathy, alopecia) while awaiting mycology results 3.

Treatment Algorithm

First-Line Oral Therapy (Required)

Topical therapy alone is inadequate for tinea capitis—oral antifungal therapy is mandatory to achieve clinical and mycological cure 3, 2.

Choice depends on the causative organism:

If Trichophyton species (most common in many regions):

• Terbinafine is first-line 3, 2
  • < 20 kg: 62.5 mg daily for 2-4 weeks
  • 20-40 kg: 125 mg daily for 2-4 weeks

  • 40 kg: 250 mg daily for 2-4 weeks

If Microsporum species:

• Griseofulvin is more effective 3
  • < 50 kg: 15-20 mg/kg/day for 6-8 weeks

  • 50 kg: 1 g daily for 6-8 weeks

Start with terbinafine empirically if organism is unknown, as it requires shorter treatment duration (improving compliance) and is effective for the most common pathogens 3.

Adjunctive Topical Therapy

Add antifungal shampoos to reduce spore transmission 3:

• Ketoconazole 2% shampoo
• Selenium sulfide 1% shampoo
• Povidone-iodine shampoo

Special Considerations with Vitiligo

Immunosuppressive Therapy Risk

If the patient is using topical ruxolitinib cream (JAK inhibitor) for vitiligo treatment, this creates local immunosuppression that may predispose to fungal infections 1. Consider:

• Temporarily discontinuing ruxolitinib in the affected area during antifungal treatment
• More aggressive antifungal therapy may be warranted
• Monitor closely for treatment failure

Vitiligo Does NOT Require Treatment Modification

The depigmented skin from vitiligo itself does not alter tinea treatment 5. Standard antifungal regimens remain appropriate.

Avoid Combination Products

Never use topical corticosteroid-antifungal combinations in this scenario 2. The patient may be using topical corticosteroids for vitiligo, but these should not be applied to areas with active tinea infection, as steroids can worsen fungal infections.

Treatment Failure Management

If no clinical improvement after completing initial therapy 3:

1. Assess compliance and drug absorption
2. Consider organism resistance or reinfection
3. If clinical improvement but positive mycology: Continue current therapy 2-4 weeks longer
4. If no improvement: Switch to second-line therapy
   • If started on terbinafine → switch to griseofulvin (for possible Microsporum)
   • If started on griseofulvin → switch to terbinafine (for Trichophyton)
   • Consider itraconazole 5 mg/kg/day for 2-4 weeks as alternative 3

Critical Pitfalls to Avoid

• Don't rely on visual diagnosis alone in vitiligo patients—the altered pigmentation can mask or mimic fungal infection 4
• Don't use topical antifungals as monotherapy for scalp/hairline involvement—oral therapy is essential 3
• Don't continue immunosuppressive vitiligo treatments over active fungal infection sites
• Don't assume treatment failure is due to vitiligo—it's usually compliance, wrong organism identification, or inadequate dosing 3

Monitoring and Follow-up

• Obtain post-treatment mycology to confirm clearance 3
• Monitor for Koebner phenomenon (new vitiligo at sites of trauma/inflammation from the infection)
• Resume vitiligo-specific treatments only after documented mycological cure
• Educate about preventing reinfection and transmission to others